Postdoctoral researcher in precision immuno-oncology and biomarker development

• Nijmegen
• Hybrid

We are looking for a talented and driven postdoctoral researcher to join our translational oncology research group at Radboudumc Nijmegen. Our group is committed to developing accurate data-driven decision support tools for precision immuno-oncology tailored to individual patients with thoracic malignancies based on tumour and patient characteristics.

You will play a central role in the analysis of biomarker data of the DEDICATION-1 trial (PMID: ) a clinical study in advanced-stage non-small cell lung cancer (NSCLC) with a primary focus on biomarker discovery development and validation. Your work will directly bridge laboratory findings with clinical application contributing to a future in which treatment decisions in thoracic oncology are guided by robust personalized biomarkers.

Your Responsibilities

• Represent and strengthen the corporate identity of Radboudumc in all scientific and collaborative activities.
• Take responsibility for structuring curating and safeguarding research data working closely with the research team at the Department of Pulmonary Diseases and Department of Pharmacy Pharmacology & Toxicology to ensure that datasets are organized interoperable and accessible for future projects beyond individual research interests and act as an ambassador for transparent collaborative and sustainable data practices promoting a culture of open science and longterm research continuity beyond the scope of personal interests.
• Lead and execute biomarker development analyses within the DEDICATION-1 trial integrating multi-omics immunological and clinical datasets.
• Present findings at national and international oncology and immunology conferences and publish results in peer-reviewed journals.
• Actively contribute to building and maintaining an (inter)national research consortium fostering collaborations between Radboudumc UMCU and other partner institutions.
• Identify write and apply for competitive grants and fellowships (e.g. NWO KWF Horizon Europe or industry-partnered funding).

Targets for the coming 2 years

• Biomarker development - Analyse present and publish findings from DEDICATION-1.
• Grant acquisition - Apply for and receive at least one competitive grant or award.
• Consortium building - Expand the (inter)national research network actively.
• Scientific output - Contribute to peer-reviewed publications and conference presentations.
• Data framework - Deliver a structured documented and futureproof data framework for the DEDICATION-1 trial data.

Our research group at Radboudumc is dedicated to translating scientific insights into clinical tools that improve outcomes for patients with thoracic malignancies. We operate at the interface of clinical oncology pharmacology immunopharmacology tumour immunology pathology medical imaging and data science.

In close partnership with UMCU we are an active and growing (inter)national consortium. The primary research location is Nijmegen (Radboudumc) with strong ties to Utrecht (UMCU). We value an open inclusive and collegial research culture.